Selected research
Industry Research
Non Corticosteroid Anti-inflammatory Eyedrops Industry Research Report 2026
Market perspective
The global Non Corticosteroid Anti-inflammatory Eyedrops market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Non Corticosteroid Anti-inflammatory Eyedrops is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Non Corticosteroid Anti-inflammatory Eyedrops is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Non Corticosteroid Anti-inflammatory Eyedrops is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Non Corticosteroid Anti-inflammatory Eyedrops include Novartis AG, Allergan, Inc., Walgreens, Viva Opti-Free, Visine, Systane, Staples, Similasan Corporation and Rite Aid, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Non Corticosteroid Anti-inflammatory Eyedrops market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Non Corticosteroid Anti-inflammatory Eyedrops Market by Company
Novartis AG
Allergan, Inc.
Walgreens
Viva Opti-Free
Visine
Systane
Staples
Similasan Corporation
Rite Aid
Meda Pharmaceuticals Inc
Clear eyes
Cigna
Bausch & Lomb Inc
Bausch & Lomb
Alcon
Non Corticosteroid Anti-inflammatory Eyedrops Segment by Type
Diclofenac
Mugabe
Ocufen
Others
Non Corticosteroid Anti-inflammatory Eyedrops Segment by Application
Adult
Children
Non Corticosteroid Anti-inflammatory Eyedrops Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non Corticosteroid Anti-inflammatory Eyedrops market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non Corticosteroid Anti-inflammatory Eyedrops and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non Corticosteroid Anti-inflammatory Eyedrops.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Non Corticosteroid Anti-inflammatory Eyedrops manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Non Corticosteroid Anti-inflammatory Eyedrops by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Non Corticosteroid Anti-inflammatory Eyedrops in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Diclofenac
- Mugabe
- Ocufen
- Others
Applications
- Adult
- Children
Companies covered
- Novartis AG
- Allergan, Inc.
- Walgreens
- Viva Opti-Free
- Visine
- Systane
- Staples
- Similasan Corporation
- Rite Aid
- Meda Pharmaceuticals Inc
- Clear eyes
- Cigna
- Bausch & Lomb Inc
- Bausch & Lomb
- Alcon
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Size (2021-2032)
- 2.2.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales (2021-2032)
- 2.2.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Average Price (2021-2032)
- 2.3 Non Corticosteroid Anti-inflammatory Eyedrops by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Diclofenac
- 2.3.3 Mugabe
- 2.3.4 Ocufen
- 2.3.5 Others
- 2.4 Non Corticosteroid Anti-inflammatory Eyedrops by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adult
- 2.4.3 Children
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue of Manufacturers (2021-2026)
- 3.4 Global Non Corticosteroid Anti-inflammatory Eyedrops Average Price by Manufacturers (2021-2026)
- 3.5 Global Non Corticosteroid Anti-inflammatory Eyedrops Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Non Corticosteroid Anti-inflammatory Eyedrops, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Non Corticosteroid Anti-inflammatory Eyedrops, Product Type & Application
- 3.8 Global Manufacturers of Non Corticosteroid Anti-inflammatory Eyedrops, Established Date
- 3.9 Global Non Corticosteroid Anti-inflammatory Eyedrops Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Allergan, Inc.
- 4.2.1 Allergan, Inc. Company Information
- 4.2.2 Allergan, Inc. Business Overview
- 4.2.3 Allergan, Inc. Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Allergan, Inc. Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.2.5 Allergan, Inc. Recent Developments
- 4.3 Walgreens
- 4.3.1 Walgreens Company Information
- 4.3.2 Walgreens Business Overview
- 4.3.3 Walgreens Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Walgreens Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.3.5 Walgreens Recent Developments
- 4.4 Viva Opti-Free
- 4.4.1 Viva Opti-Free Company Information
- 4.4.2 Viva Opti-Free Business Overview
- 4.4.3 Viva Opti-Free Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Viva Opti-Free Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.4.5 Viva Opti-Free Recent Developments
- 4.5 Visine
- 4.5.1 Visine Company Information
- 4.5.2 Visine Business Overview
- 4.5.3 Visine Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Visine Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.5.5 Visine Recent Developments
- 4.6 Systane
- 4.6.1 Systane Company Information
- 4.6.2 Systane Business Overview
- 4.6.3 Systane Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Systane Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.6.5 Systane Recent Developments
- 4.7 Staples
- 4.7.1 Staples Company Information
- 4.7.2 Staples Business Overview
- 4.7.3 Staples Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Staples Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.7.5 Staples Recent Developments
- 4.8 Similasan Corporation
- 4.8.1 Similasan Corporation Company Information
- 4.8.2 Similasan Corporation Business Overview
- 4.8.3 Similasan Corporation Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Similasan Corporation Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.8.5 Similasan Corporation Recent Developments
- 4.9 Rite Aid
- 4.9.1 Rite Aid Company Information
- 4.9.2 Rite Aid Business Overview
- 4.9.3 Rite Aid Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Rite Aid Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.9.5 Rite Aid Recent Developments
- 4.10 Meda Pharmaceuticals Inc
- 4.10.1 Meda Pharmaceuticals Inc Company Information
- 4.10.2 Meda Pharmaceuticals Inc Business Overview
- 4.10.3 Meda Pharmaceuticals Inc Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Meda Pharmaceuticals Inc Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.10.5 Meda Pharmaceuticals Inc Recent Developments
- 4.11 Clear eyes
- 4.11.1 Clear eyes Company Information
- 4.11.2 Clear eyes Business Overview
- 4.11.3 Clear eyes Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Clear eyes Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.11.5 Clear eyes Recent Developments
- 4.12 Cigna
- 4.12.1 Cigna Company Information
- 4.12.2 Cigna Business Overview
- 4.12.3 Cigna Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Cigna Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.12.5 Cigna Recent Developments
- 4.13 Bausch & Lomb Inc
- 4.13.1 Bausch & Lomb Inc Company Information
- 4.13.2 Bausch & Lomb Inc Business Overview
- 4.13.3 Bausch & Lomb Inc Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bausch & Lomb Inc Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.13.5 Bausch & Lomb Inc Recent Developments
- 4.14 Bausch & Lomb
- 4.14.1 Bausch & Lomb Company Information
- 4.14.2 Bausch & Lomb Business Overview
- 4.14.3 Bausch & Lomb Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bausch & Lomb Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.14.5 Bausch & Lomb Recent Developments
- 4.15 Alcon
- 4.15.1 Alcon Company Information
- 4.15.2 Alcon Business Overview
- 4.15.3 Alcon Non Corticosteroid Anti-inflammatory Eyedrops Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Alcon Non Corticosteroid Anti-inflammatory Eyedrops Product Portfolio
- 4.15.5 Alcon Recent Developments
5 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Scenario by Region
- 5.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region: 2021-2032
- 5.2.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region: 2021-2026
- 5.2.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Region: 2027-2032
- 5.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region: 2021-2032
- 5.3.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region: 2021-2026
- 5.3.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Region: 2027-2032
- 5.4 North America Non Corticosteroid Anti-inflammatory Eyedrops Market Facts & Figures by Country
- 5.4.1 North America Non Corticosteroid Anti-inflammatory Eyedrops Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 5.4.3 North America Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Non Corticosteroid Anti-inflammatory Eyedrops Market Facts & Figures by Country
- 5.5.1 Europe Non Corticosteroid Anti-inflammatory Eyedrops Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 5.5.3 Europe Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Market Facts & Figures by Country
- 5.6.1 Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Non Corticosteroid Anti-inflammatory Eyedrops Market Facts & Figures by Country
- 5.7.1 South America Non Corticosteroid Anti-inflammatory Eyedrops Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 5.7.3 South America Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type (2021-2032)
- 6.1.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Type (2021-2032)
- 6.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Type (2021-2032)
- 6.2.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Type (2021-2032)
- 6.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application (2021-2032)
- 7.1.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales Market Share by Application (2021-2032)
- 7.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue by Application (2021-2032)
- 7.2.1 Global Non Corticosteroid Anti-inflammatory Eyedrops Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Non Corticosteroid Anti-inflammatory Eyedrops Revenue Market Share by Application (2021-2032)
- 7.3 Global Non Corticosteroid Anti-inflammatory Eyedrops Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Non Corticosteroid Anti-inflammatory Eyedrops Value Chain Analysis
- 8.1.1 Non Corticosteroid Anti-inflammatory Eyedrops Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Non Corticosteroid Anti-inflammatory Eyedrops Production Mode & Process
- 8.2 Non Corticosteroid Anti-inflammatory Eyedrops Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Non Corticosteroid Anti-inflammatory Eyedrops Distributors
- 8.2.3 Non Corticosteroid Anti-inflammatory Eyedrops Customers
9 Global Non Corticosteroid Anti-inflammatory Eyedrops Analyzing Market Dynamics
- 9.1 Non Corticosteroid Anti-inflammatory Eyedrops Industry Trends
- 9.2 Non Corticosteroid Anti-inflammatory Eyedrops Industry Drivers
- 9.3 Non Corticosteroid Anti-inflammatory Eyedrops Industry Opportunities and Challenges
- 9.4 Non Corticosteroid Anti-inflammatory Eyedrops Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst